Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice

Suguru Yamamoto, Yiqin Zuo, Ji Ma, Patricia G. Yancey, Tracy E. Hunley, Masaru Motojima, Agnes B. Fogo, MacRae F. Linton, Sergio Fazio, Iekuni Ichikawa, Valentina Kon

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Background. Accelerated atherosclerosis and increased cardiovascular events are not only more common in chronic kidney disease (CKD) but are more resistant to therapeutic interventions effective in the general population. The oral charcoal adsorbent, AST-120, currently used to delay start of dialysis, reduces circulating and tissue uremic toxins, which may contribute to vasculopathy, including atherosclerosis. We, therefore, investigated whether AST-120 affects CKD-induced atherosclerosis.Methods. Apolipoprotein E-deficient mice, a model of atherosclerosis, underwent uninephrectomy, subtotal nephrectomy or sham operation at 8 weeks of age and were treated with AST-120 after renal ablation. Atherosclerosis and its characteristics were assessed at 25 weeks of age.Results. Uninephrectomy and subtotal nephrectomised mice had significantly increased acceleration of atherosclerosis. AST-120 treatment dramatically reduced the atherosclerotic burden in mice with kidney damage, while there was no beneficial effect in sham-operated mice. The benefit was independent of blood pressure, serum total cholesterol or creatinine clearance. AST-120 significantly decreased necrotic areas and lessened aortic deposition of the uremic toxin indoxyl sulfate without affecting lesional macrophage or collagen content. Furthermore, AST-120 lessened aortic expression of monocyte chemoattractant protein-1, tumor necrosis factor-α and interleukin-1β messenger RNA.Conclusions. AST-120 lessens the extent of atherosclerosis induced by kidney injury and alters lesion characteristics in apolipoprotein E-deficient mice, resulting in plaques with a more stable phenotype with less necrosis and reduced inflammation.

Original languageEnglish (US)
Pages (from-to)2491-2497
Number of pages7
JournalNephrology Dialysis Transplantation
Volume26
Issue number8
DOIs
StatePublished - Aug 2011
Externally publishedYes

Fingerprint

Charcoal
Kidney Diseases
Apolipoproteins E
Atherosclerosis
Chronic Renal Insufficiency
Kidney
Indican
Chemokine CCL2
AST 120
Nephrectomy
Interleukin-1
Dialysis
Creatinine
Necrosis
Collagen
Tumor Necrosis Factor-alpha
Macrophages
Cholesterol
Blood Pressure
Inflammation

Keywords

  • AST-120
  • atherosclerosis
  • charcoal adsorbent
  • necrotic lesion
  • renal ablation

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice. / Yamamoto, Suguru; Zuo, Yiqin; Ma, Ji; Yancey, Patricia G.; Hunley, Tracy E.; Motojima, Masaru; Fogo, Agnes B.; Linton, MacRae F.; Fazio, Sergio; Ichikawa, Iekuni; Kon, Valentina.

In: Nephrology Dialysis Transplantation, Vol. 26, No. 8, 08.2011, p. 2491-2497.

Research output: Contribution to journalArticle

Yamamoto, Suguru ; Zuo, Yiqin ; Ma, Ji ; Yancey, Patricia G. ; Hunley, Tracy E. ; Motojima, Masaru ; Fogo, Agnes B. ; Linton, MacRae F. ; Fazio, Sergio ; Ichikawa, Iekuni ; Kon, Valentina. / Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice. In: Nephrology Dialysis Transplantation. 2011 ; Vol. 26, No. 8. pp. 2491-2497.
@article{4f67d785cfc7456c84fa4abf7c9fb88c,
title = "Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice",
abstract = "Background. Accelerated atherosclerosis and increased cardiovascular events are not only more common in chronic kidney disease (CKD) but are more resistant to therapeutic interventions effective in the general population. The oral charcoal adsorbent, AST-120, currently used to delay start of dialysis, reduces circulating and tissue uremic toxins, which may contribute to vasculopathy, including atherosclerosis. We, therefore, investigated whether AST-120 affects CKD-induced atherosclerosis.Methods. Apolipoprotein E-deficient mice, a model of atherosclerosis, underwent uninephrectomy, subtotal nephrectomy or sham operation at 8 weeks of age and were treated with AST-120 after renal ablation. Atherosclerosis and its characteristics were assessed at 25 weeks of age.Results. Uninephrectomy and subtotal nephrectomised mice had significantly increased acceleration of atherosclerosis. AST-120 treatment dramatically reduced the atherosclerotic burden in mice with kidney damage, while there was no beneficial effect in sham-operated mice. The benefit was independent of blood pressure, serum total cholesterol or creatinine clearance. AST-120 significantly decreased necrotic areas and lessened aortic deposition of the uremic toxin indoxyl sulfate without affecting lesional macrophage or collagen content. Furthermore, AST-120 lessened aortic expression of monocyte chemoattractant protein-1, tumor necrosis factor-α and interleukin-1β messenger RNA.Conclusions. AST-120 lessens the extent of atherosclerosis induced by kidney injury and alters lesion characteristics in apolipoprotein E-deficient mice, resulting in plaques with a more stable phenotype with less necrosis and reduced inflammation.",
keywords = "AST-120, atherosclerosis, charcoal adsorbent, necrotic lesion, renal ablation",
author = "Suguru Yamamoto and Yiqin Zuo and Ji Ma and Yancey, {Patricia G.} and Hunley, {Tracy E.} and Masaru Motojima and Fogo, {Agnes B.} and Linton, {MacRae F.} and Sergio Fazio and Iekuni Ichikawa and Valentina Kon",
year = "2011",
month = "8",
doi = "10.1093/ndt/gfq759",
language = "English (US)",
volume = "26",
pages = "2491--2497",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice

AU - Yamamoto, Suguru

AU - Zuo, Yiqin

AU - Ma, Ji

AU - Yancey, Patricia G.

AU - Hunley, Tracy E.

AU - Motojima, Masaru

AU - Fogo, Agnes B.

AU - Linton, MacRae F.

AU - Fazio, Sergio

AU - Ichikawa, Iekuni

AU - Kon, Valentina

PY - 2011/8

Y1 - 2011/8

N2 - Background. Accelerated atherosclerosis and increased cardiovascular events are not only more common in chronic kidney disease (CKD) but are more resistant to therapeutic interventions effective in the general population. The oral charcoal adsorbent, AST-120, currently used to delay start of dialysis, reduces circulating and tissue uremic toxins, which may contribute to vasculopathy, including atherosclerosis. We, therefore, investigated whether AST-120 affects CKD-induced atherosclerosis.Methods. Apolipoprotein E-deficient mice, a model of atherosclerosis, underwent uninephrectomy, subtotal nephrectomy or sham operation at 8 weeks of age and were treated with AST-120 after renal ablation. Atherosclerosis and its characteristics were assessed at 25 weeks of age.Results. Uninephrectomy and subtotal nephrectomised mice had significantly increased acceleration of atherosclerosis. AST-120 treatment dramatically reduced the atherosclerotic burden in mice with kidney damage, while there was no beneficial effect in sham-operated mice. The benefit was independent of blood pressure, serum total cholesterol or creatinine clearance. AST-120 significantly decreased necrotic areas and lessened aortic deposition of the uremic toxin indoxyl sulfate without affecting lesional macrophage or collagen content. Furthermore, AST-120 lessened aortic expression of monocyte chemoattractant protein-1, tumor necrosis factor-α and interleukin-1β messenger RNA.Conclusions. AST-120 lessens the extent of atherosclerosis induced by kidney injury and alters lesion characteristics in apolipoprotein E-deficient mice, resulting in plaques with a more stable phenotype with less necrosis and reduced inflammation.

AB - Background. Accelerated atherosclerosis and increased cardiovascular events are not only more common in chronic kidney disease (CKD) but are more resistant to therapeutic interventions effective in the general population. The oral charcoal adsorbent, AST-120, currently used to delay start of dialysis, reduces circulating and tissue uremic toxins, which may contribute to vasculopathy, including atherosclerosis. We, therefore, investigated whether AST-120 affects CKD-induced atherosclerosis.Methods. Apolipoprotein E-deficient mice, a model of atherosclerosis, underwent uninephrectomy, subtotal nephrectomy or sham operation at 8 weeks of age and were treated with AST-120 after renal ablation. Atherosclerosis and its characteristics were assessed at 25 weeks of age.Results. Uninephrectomy and subtotal nephrectomised mice had significantly increased acceleration of atherosclerosis. AST-120 treatment dramatically reduced the atherosclerotic burden in mice with kidney damage, while there was no beneficial effect in sham-operated mice. The benefit was independent of blood pressure, serum total cholesterol or creatinine clearance. AST-120 significantly decreased necrotic areas and lessened aortic deposition of the uremic toxin indoxyl sulfate without affecting lesional macrophage or collagen content. Furthermore, AST-120 lessened aortic expression of monocyte chemoattractant protein-1, tumor necrosis factor-α and interleukin-1β messenger RNA.Conclusions. AST-120 lessens the extent of atherosclerosis induced by kidney injury and alters lesion characteristics in apolipoprotein E-deficient mice, resulting in plaques with a more stable phenotype with less necrosis and reduced inflammation.

KW - AST-120

KW - atherosclerosis

KW - charcoal adsorbent

KW - necrotic lesion

KW - renal ablation

UR - http://www.scopus.com/inward/record.url?scp=79959368409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959368409&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfq759

DO - 10.1093/ndt/gfq759

M3 - Article

C2 - 21245127

AN - SCOPUS:79959368409

VL - 26

SP - 2491

EP - 2497

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 8

ER -